诊室环境下经皮胫神经刺激治疗膀胱过度活动症的真实世界经验
本研究回顾性分析了113例接受经皮胫神经刺激(PTNS)治疗膀胱过度活动症(OAB)症状的成人患者,平均完成10.5±3次计划12次周治疗,6周时71.3%、12周时70.6%的患者症状减轻,但维持治疗依从性有限,最常见的不依从原因为疗效不足。
要点
- 113例患者平均完成10.5±3次计划12次周治疗,75.6%完成全部12次周治疗。
- 6周时71.3%、12周时70.6%的患者症状减轻,但仅54.9%完成中位3次月度维持治疗。
- 就诊自付费用、就业状态和诊所距离与未完成周治疗或未进入月度维持治疗无关。
核心结论
- 多数患者每周PTNS后症状减轻,但对维持治疗的不依从和疗效不足可能限制长期可行性。
- 自付费用和就诊距离与不依从无关。
研究设计与样本
- 回顾性审查2011年6月30日至2015年10月8日接受PTNS的成人患者,共113例,平均年龄75±12岁。
- 采用Pearson卡方检验、Fisher精确检验、Wilcoxon秩和检验和配对t检验。
主要发现
- 113例中女性65.5%、已婚78.1%、退休或失业80.2%,至诊所中位距离8.1英里,中位自付费用0美元。
- PTNS最常见适应证为夜尿症(92.9%),其次为伴急迫性尿失禁的OAB(75.2%)和尿急和/或尿频(24.8%)。
- 既往治疗包括抗胆碱能药(75.2%)、米拉贝隆(36.6%)、行为调整(29.2%)、盆底物理治疗(18.6%)及其他(19.5%)。
- 105例中40例(38.1%)使用伴随治疗(最常见为抗胆碱能药);87例中62例(71.3%)6周时症状减轻,85例中60例(70.6%)12周时症状减轻。
- 82例(75.6%)完成全部12次周治疗,45例(54.9%)完成中位3次月度维持治疗;不依从最常见原因为疗效不足。
临床怎么用
- 诊室环境下PTNS可使多数OAB患者周治疗后症状减轻,但需关注维持治疗依从性和疗效不足问题。
- 就诊自付费用和距离未影响治疗完成情况,可据此与患者沟通治疗安排。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the outcomes and compliance with percutaneous tibial nerve stimulation (PTNS) for overactive bladder (OAB) symptoms. METHODS: Adults who had PTNS from June 30, 2011, to October 8, 2015, were retrospectively reviewed for demographics, copay, travel distance, employment status, history, symptoms, and treatments used before, during, and after PTNS. Pearson chi-square test, Fisher exact test, Wilcoxon rank and paired t test were performed. RESULTS: Of 113 patients (mean age 75 ± 12 years), most were women (65.5%), married (78.1%), and retired or unemployed (80.2%). The median distance to the clinic was 8.1 mi, and the median copay was $0. The most common indication for PTNS was nocturia (92.9%) followed by OAB with urgency urinary incontinence (75.2%) and urinary urgency and/or frequency (24.8%). Prior treatments included anticholinergics (75.2%), mirabegron (36.6%), behavioral modification (29.2%), pelvic floor physical therapy (18.6%), and others (19.5%). Patients completed a mean of 10.5 ± 3 of 12 planned weekly PTNS treatments. Of 105 patients, 40 (38.1%) used concomitant treatments (most commonly anticholinergics). Of 87 patients, 62 (71.3%) had decreased symptoms at 6 weeks, and of 85 patients, 60 (70.6%) had decreased symptoms at 12 weeks. The majority (82; 75.6%) completed all 12 weekly treatments and 45 (54.9%) completed 3 (median) monthly maintenance treatments. The most common reason for noncompliance was lack of efficacy. Visit copay, employment status, and distance to the clinic were not associated with failure to complete weekly treatments or progression to monthly maintenance. CONCLUSION: Although most patients' symptoms decreased after weekly PTNS, nonadherence to maintenance and lack of efficacy may limit long-term feasibility. Copay and distance traveled were not associated with noncompliance.
引用
- Sirls ER, Killinger KA, Boura JA, et al. Percutaneous Tibial Nerve Stimulation in the Office Setting: Real-world Experience of Over 100 Patients. Urology. 2017. PMID: 29196071. doi:10.1016/j.urology.2017.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。